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Background: Probiotics are defined as live microorganisms that may confer health benefits when ingested.
Meta-analysis of probiotic trials suggests a 25 % lower ventilator-associated pneumonia (VAP) and 18 % lower
infection rates overall when administered to patients in the intensive care unit (ICU). However, prior trials are
small, largely single center, and at high risk of bias. Before a large rigorous trial is launched, testing whether
probiotics confer benefit, harm, or have no impact, a pilot trial is needed. The aim of the PROSPECT Pilot Trial is
to determine the feasibility of performing a larger trial in mechanically ventilated critically ill patients investigating
Lactobacillus rhamnosus GG. A priori, we determined that the feasibility of the larger trial would be based on
timely recruitment, high protocol adherence, minimal contamination, and an acceptable VAP rate.
Methods/design: Patients ≥18 years old in the ICU who are anticipated to receive mechanical ventilation for ≥72 hours
will be included. Patients are excluded if they are at increased risk of probiotic-associated infection, have strict
enteral medication contraindications, are pregnant, previously enrolled in a related trial, or are receiving palliative
care. Following informed consent, patients are randomized in variable unspecified block sizes in a fixed 1:1 ratio,
stratified by ICU, and medical, surgical, or trauma admitting diagnosis. Patients receive 1 × 1010 colony forming
units of L. rhamnosus GG (Culturelle, Locin Industries Ltd) or an identical placebo suspended in tap water administered
twice daily via nasogastric tube in the ICU. Clinical and research staff, patients, and families are blinded.
Discussion: The primary outcomes for this pilot trial are the following: (1) recruitment success, (2) ≥90 % protocol
adherence, (3) ≤5 % contamination, and (4) ~10 % VAP rate. Additional clinical outcomes are VAP, other infections,
diarrhea (total, antibiotic associated, and Clostridium difficile), ICU and hospital length of stay, and mortality.
The morbidity, mortality, and cost of VAP underscore the need for cost-effective prophylactic interventions. The
PROSPECT Pilot Trial is the initial step toward rigorously evaluating whether probiotics decrease nosocomial infections,
have no effect, or actually cause infections in critically ill patients.
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Keywords: Critically ill, Intensive care, Probiotics, Infection, Pneumonia* Correspondence: debcook@mcmaster.ca
4Department of Medicine, McMaster Health Sciences Center, Room 2C11,
1200 Main Street W, Hamilton, Ontario, Canada
5Department of Clinical Epidemiology & Biostatistics, McMaster University,
Hamilton, Canada
Full list of author information is available at the end of the article
© 2015 Johnstone et al.
Johnstone et al. Pilot and Feasibility Studies  (2015) 1:19 Page 2 of 7Background
Ventilator-associated pneumonia (VAP) is the most
common nosocomial infection in the intensive care unit
(ICU), resulting in a high burden of illness. In a 2005
systematic review, the pooled cumulative incidence of
VAP was 23 % (95 % confidence interval (CI) 18.8 %–
26.9 %) in randomized controlled trials (RCTs) and 10 %
(95%CI 7.0–12.5 %) in observational studies [1]. In
addition, VAP is associated with a two-fold attributable
risk of dying in the ICU (odds ratio (OR) 2.02, 95 % CI
1.16–3.56), and the cost attributed to VAP ranges from
US $10,000–$13,000 per patient [1]. Thus, VAP preven-
tion is an important patient safety goal for critically ill
patients [2, 3].
Probiotics, which are live microorganisms thought to
have health benefits when ingested, [4] have emerged as
a potential strategy to prevent VAP, potentially through
enhancing gut barrier function and reducing pathogenic
bacterial load [5, 6]. An early systematic review and
meta-analysis of RCTs evaluating the efficacy of probio-
tics on VAP prevention in the ICU conducted in 2010
that included five RCTs showed that probiotics com-
pared with control (placebo or other) reduced the inci-
dence of VAP in mechanically ventilated patients (60/
316 (19 %) versus 102/373 (27 %), OR 0.55, 95 % CI
0.31–0.98, I2 39 %) [7]. The most rigorous RCT to date
compared a combination of oropharyngeal plus gastric
Lactobacillus rhamnosus GG to corresponding placebos
in 146 patients expected to remain intubated for at least
72 hours (a group at relatively high risk of VAP) [8].
Those patients treated with L. rhamnosus GG had lower
rates of VAP (17/73 (23 %) versus 33/73 (45 %), relative
risk (RR) 0.46, 95 % CI 0.26–0.82). This trial suggests
that L. rhamnosus GG, specifically, is a promising
probiotic to prevent VAP in a selected high-risk ICU
population.
Our recent meta-analysis of RCTs in the ICU suggests
that probiotics administered to critically ill mechanically
ventilated patients are associated with a 25 % lower VAP
rate (95 % CI 3–41 %) and 18 % lower infection rates
overall (95 % CI 1–31 %) [9]. However, the finding that
probiotics may prevent VAP arise from seven small
(n = 50–300), mostly low quality single-center RCTs
yielding imprecise estimates and results with uncertain
internal and external validity.
Given the effectiveness of probiotics in the community
and hospital setting [10–13], yet uncertain benefits in
the ICU, a large rigorous RCT is needed. Before launch-
ing a complex costly RCT testing whether probiotics
confer benefit, harm, or have no impact on infectious
and non-infectious outcomes, a pilot trial is crucial. To
this end, we sought to determine whether it is feasible to
perform a large RCT in mechanically ventilated critically
ill patients to investigate whether orally ingested L.rhamnosus GG prevents VAP based on successful and
timely pilot trial recruitment, high adherence to proto-
col, minimal contamination, and an acceptable VAP rate
in the Probiotics: Prevention of Severe Pneumonia and
Endotracheal Colonization (PROSPECT) Pilot Trial. Ul-
timately, if the pilot trial is successful, the main trial will
aim to determine, among mechanically ventilated critically
ill patients, the effect of orally ingested L. rhamnosus GG
compared to placebo on VAP and other ICU-acquired in-
fections, diarrhea (including total, antibiotic associated
and C. difficile), the duration of mechanical ventilation,
ICU and hospital stay, and ICU and hospital mortality
(PROSPECT Trial NCT01782755).
Methods/design
Study design
We are conducting a parallel group blinded pilot RCT in
14 ICUs in Canada and the United States. Patients are
randomized to placebo or probiotic in a fixed allocation
ratio of 1:1 using a computer based random number
generator produced on the RANDOMIZE.NET website.
Randomization is concealed and stratified by ICU and
by medical, surgical, or trauma status, in variable un-
specified block sizes. Research Coordinators screen all
ventilated patients during weekdays. A de-identified log
of screened patients is kept, recording each inclusion/ex-
clusion criteria. Reasons for being eligible non-randomized
are recorded. Once the Research Coordinator determines
that a patient is truly eligible, s/he obtains written informed
a priori consent either from the patient or substitute deci-
sion maker then notifies the local study pharmacist who
performs the randomization.
After randomization, an identical placebo ensures
blinding of all possible parties (patient, family, bedside
clinicians, laboratory and research personnel, the biostat-
istician and data analyst).
Eligibility
Inclusion criteria:
1. Adults ≥18 years old in the ICU;
2. Mechanically ventilated with anticipated ventilation
of ≥72 hours at enrolment.
Exclusion criteria:
1. Mechanical ventilation exceeding 72 hours at time
of screening;
2. Increased risk of iatrogenic probiotic infection
including specific immunocompromised populations
(HIV <200 CD4 cells/μL, chronic
immunosuppressive medications, prior organ or
hematological transplant, neutropenia (absolute
neutrophil count <500);
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rheumatic heart disease, congenital heart defect,
mechanical valves, endocarditis, endovascular grafts,
permanent endovascular devices such as permanent
(not short-term) hemodialysis catheters, pacemakers
or defibrillators);
4. Mucosal gastrointestinal tract defects
(gastroesophageal or intestinal injury, including
active bleeding), surgery of the esophagus, stomach,
small or large bowel, liver, gallbladder, hepatobiliary
tree, spleen, or pancreas within 72 hours, suspected
or documented ischemic gut and severe acute
pancreatitis, [14]);
5. Strict contraindication or inability to receive enteral
medications;
6. Pregnancy;
7. Intent to withdraw advanced life support;
8. Enrolment in this or an ongoing related trial.
Trial interventions
Patients allocated to the intervention receive 1 × 1010 col-
ony forming units (CFU) of L. rhamnosus GG (Culturelle,
Locin Industries Ltd) in one capsule suspended in tap
water, administered via nasogastric or nasoduodenal tube
twice daily in the ICU. L. rhamnosus GG, a variant to L.
casei rhamnosus is the most widely studied in adults and
children [15]. L. rhamnosus GG is approved in Canada for
managing and preventing antibiotic-associated diarrhea
(Health Canada Natural Product #80011341). The most
rigorous RCT to date investigating probiotics for the pre-
vention of VAP used L. rhamnosus GG as the interven-
tion, and the results of this pilot trial suggest that L.
rhamnosus GG is a promising option for preventing VAP
[8]. Furthermore, recent in vivo studies showed that a dose
of L. rhamnosus GG of ≥1 × 109 was optimal to reduce
bacteremia and mortality from peritonitis and pneumonia
[16]. This dose could reduce intestinal epithelial apoptosis
and restore colonic epithelial cell proliferation and at-
tenuate the local and systemic inflammatory response,
potentially by downregulation of TLR-2/TLR-4 signalling
pathway in the colon. [16]. The dose we are using is higher
than the dose showing prevention of VAP in the Morrow
RCT (total of four billion L. rhamnosus GG) [8] and the
same dose as another RCT investigating L. rhamnosus GG
in ICU patients as a potential therapy for diarrhea (total of
20 billion L. rhamnosus GG) [17]. Neither trial observed ad-
verse events related to L. rhamnosus GG [8, 17].
Patients allocated to placebo will receive microcrystal-
line cellulose, which will also be suspended in tap water,
identical in appearance and consistency to the probiotic,
and similarly administered. The placebo is prepared by
the manufacturer of L. rhamnosus GG, Culturelle, as
used in a recent trial [8]. Patients will receive the study
product until (1) death or discharge from ICU, or (2)isolation of Lactobacillus spp. cultured from a sterile site
or reported as the sole or predominant organism in a
culture from a non-sterile site or, (3) 60 days post
randomization.
To ensure consistency and document that the pro-
biotic dose matches the label, one capsule from every 10
sheets is being cultured and quantified in the Surette
Laboratory at McMaster University.
Outcomes
The four feasibility outcomes will be:
1. Recruitment of trial patients. Successful recruitment
is defined as ≥2 patients per month (total from any
study site) on average. This outcome is important
because unforeseen enrolment challenges are crucial
to identify in a pilot RCT. Unrealistic projected
recruitment rates for large studies lead to trial
fatigue, threaten non-completion, and generate
major cost overruns. Screening logs are being
reviewed monthly and eligible non-randomized
patients are examined. Barriers to enrolment are
discussed and strategies to improve recruitment are
being devised. We will calculate the mean (standard
deviation) number recruited across all recruiting
centers per month.
2. Adherence to protocol. Successful adherence is
defined as ≥90 % of the prescribed intervention
being administered. There are many reasons why
ICU patients do not receive drugs administered
through the feeding tube. Research Coordinators
determine doses actually received and reasons for
non-administration using taxonomy. If patients
cannot tolerate continuous enteral feeds, they will
still usually be able to receive the study product in a
small volume of fluid, akin to administering pills or
capsule medications. Understandable protocol devia-
tions (e.g., patient died) are being distinguished from
protocol violations (e.g., missed doses). We will
calculate an overall proportion of doses received
divided by total doses prescribed (with 95 %
confidence interval).
3. Contamination. Success is defined if <5 % of patients
have any non-study open-label probiotic, in either
group, during the ICU stay. The proportion of pa-
tients contaminated with any open-label probiotic is
being recorded by Research Coordinators daily. We
will calculate the total number of patients who ever
had open-label probiotics as a proportion (with 95 %
confidence intervals) of all randomized patients.
4. VAP. Success is defined if >10 % patients develop
VAP overall. This outcome is important because the
widely cited data by quality of care and patient safety
initiatives are biased by underreporting, generating
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trial outcome would make the sample size
prohibitively large. A valid contemporaneous rate of
VAP will be essential to calculate the sample size for a
future large trial. We will calculate the proportion of
patients with VAP (with 95 % confidence intervals).
Research Coordinators are submitting relevant clinical,
radiologic, and microbiologic data to the Methods
Center from patients with clinically suspected VAP
when there is a new, progressive or persistent
radiographic infiltrate with no other obvious cause
and the presence of any two of the following
symptoms or signs: (1) fever (temperature >38 °C)
or hypothermia (temperature <36 °C), (2) relative
neutropenia (<3.0 × 106/L) or leukocytosis
(>10 × 106/L), and (3) purulent sputum [18]. VAP
will also be classified several other ways such as
clinically suspected and treated VAP, according to
the Clinical Pulmonary Infection Score [19] and as
adjudicated by independent blinded physicians
using previous methods [20–22].
No significance testing between groups is needed to
analyze these feasibility objectives. Analyses will be per-
formed at the end of the trial on the cohort of enrolled
patients; data will not be divided by allocation group to
retain the blinding. No interim analyses or subgroup
analyses are planned due to the short duration and sam-
ple size of this pilot trial.
Clinical outcomes
These outcomes are being recorded in the PROSPECT
Pilot Trial as well as the main trial.
1. VAP as described above;
2. Other infections defined using an adaptation of the
International Sepsis Forum Consensus Conference
on Definitions of Infections in the ICU [22];
3. C. difficile-associated diarrhea defined as three or
more episodes of unformed stools in ≤24 hours, and
C. difficile toxin positive stool or colonoscopic or
histopathologic findings demonstrating pseudomem-
branous colitis [23];
4. Antibiotic-associated diarrhea defined as more than
two liquid stools a day for three or more days in
quantities in excess of normal for each patient [24];
5. Diarrhea according to the Bristol Stool Chart (1–7);
6. Duration of mechanical ventilation, length of ICU
stay, and length of hospital stay;
7. ICU mortality and in-hospital mortality.
Serious adverse events
The rationale for our approach to serious adverse events
(SAEs) accord with our guidelines for academic criticalcare trials of common interventions [25]. Thus, defined
a priori, plausible SAEs have been incorporated as trial
outcomes. Any other events that ICU physicians or Site
Investigators label as SAEs will be described fully. Any
cultures by the ICU team found to be positive for
Lactobacillus spp. will have the sample sequenced to
determine whether it is consistent with the adminis-
tered L. rhamnosus GG strain. Lactobacillus spp. identi-
fied in a sterile site or cultured as the sole or predominant
organism in a non-sterile site will prompt study product
discontinuation.Follow-up
Patients are being reviewed daily by the Research Coord-
inator in ICU, where most information is collected. This
involves baseline data (e.g., demographics, illness severity,
advanced life support), daily data (e.g., study intervention
administration and reasons why not administered, nutri-
tional route, relevant medications including antibiotics,
agents that may increase gut motility (e.g., prokinetics,
laxatives) or decrease gut motility (e.g., opiate infusions),
VAP prevention co-interventions, culture results, clinical
diagnoses, diarrhea episodes, length of stay, mortality),
and Methods Center data (e.g., infection adjudication
forms). Any reasons for protocol non-compliance are re-
corded daily, along with any contamination by non-study
probiotic. Co-interventions will likely be comparable be-
tween groups, given the blinded design, but they are re-
corded daily, including other VAP prevention strategies
and antibiotics (type, dose, frequency and duration). We
do not anticipate any patients lost to follow-up given the
hospital time horizon for vital status ascertainment and
the ICU stay for key data collection.Ethics
The protocol has been approved by each hospital’s Re-
search Ethics Board using an a priori consent model.
PROSPECT is being conducted in accordance with Good
Clinical Practice following the Tri-council Guidelines.
This is an investigator-initiated trial funded from four
peer review sources to minimize possible financial con-
flict of interests. Probiotic and placebo were donated by
iHealth, the distributers of Culturelle’s L. rhamnosus GG
product.
This Pilot Trial does not have a Data Safety and Moni-
toring Committee (DSMC) due to its size and duration.
The larger trial’s independent DSMC will create a charter
[26] outlining roles, responsibilities, and reporting rela-
tionships. For the future large trial, the Trial Biostatistician
will provide the DSMC with blinded reports of protocol
adherence (e.g., randomization, crossovers, etc.), manage-
ment indicators (e.g., consent rate, data completion), and
clinical outcomes (in interim and final analyses).
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Our approach to sample size for a pilot trial focused on
feasibility was based on interpreting the lower bound of
confidence intervals around estimates [27]—in this case,
around the feasibility objective of adherence to protocol,
whereby successful adherence is defined as ≥90 % of the
prescribed intervention being administered. Using patient
as the unit of analysis, rather than doses prescribed, the
PROSPECT Pilot Trial sample size calculation claims
feasibility if at least 80 % of the patients can achieve suc-
cessful protocol adherence. Recruiting only 150 patients
gives an estimate of the proportion of patients with suc-
cessful adherence with a margin of error between 0.05 and
0.06 in a 95 % CI with a lower bound of 0.84 [Appendix].
However, we increased the sample size into the vanguard
Pilot Trial phase to enrol 250 patients in 14 ICUs, for the
following reasons: (1) to be sure that at a large number of
centers, there is sufficient Research Coordinator exposure
to the protocol; (2) to identify any feasibility challenges
with data collection methods for the various complex
nosocomial infections that could occur at any of the cen-
ters with different referral patterns and case mix; and (3)
to be sure that we can evaluate our key feasibility objec-
tives in both Canada and the United States [28].
For the future main PROSPECT Trial, the target sam-
ple size will be 2650 patients. Based on an estimated
15 % VAP rate, 1325 patients in each group (n = 2650)
will be enrolled to detect a 25 % relative risk reduction
with 80 % power (alpha 0.05, beta 0.80), using a two-
tailed chi-square test.Management
To ensure protocol adherence and data quality, training
sessions were held for all research personnel using pro-
cedures manuals, standard operating procedures, slide
decks, and a study website. The PROSPECT Steering
Committee is responsible for the conduct of this PRO-
SPECT Pilot Trial, for upholding or modifying study
procedures as needed, addressing challenges with proto-
col implementation, refining the protocol as needed, and
reviewing the data. Steering Committee meetings are
held in-person or by conference call quarterly. The Clin-
ical Advances through Research and Information Transla-
tion (CLARITY) Research Group at McMaster University
is responsible for overall management. We have the
requisite breadth and depth of knowledge in study design,
implementation, and biostatistics. Our faculty and staff
have a wealth of experience in implementation of pilot
studies and large international, national, and provincial
randomized trials and observational studies. CLARITY
has extensive experience and published on calibration,
adjudication and efficiencies therein for VAP [21], bleed-
ing [28], lung cancer [29], and thrombosis [30–32]. ThePROSPECT Pilot Trial is conducted under the auspices of
the Canadian Critical Care Trials Group [33, 34].Discussion
Pilot trials have served the Canadian Critical Care Trials
Group well [27, 35], preparing for larger trials. If all four
of our PROSPECT Pilot Trial feasibility objectives are
attained, we will be well positioned to pursue the main
trial. If any of our feasibility objectives are not met, we
will rework the protocol in collaboration with the
CCCTG and only move forward if the barriers can be
properly addressed. The PROSPECT Pilot Trial takes a
financially responsible approach to establish research ef-
ficiencies and economies of scale before costly grant ap-
plications are prepared. If the pilot RCT does not
identify a need for any substantive protocol changes, this
will be an internal pilot [35]. Accordingly, we will not
analyze or report clinical outcomes from the pilot trial;
we will include these patient data in the analyses of the
main PROSPECT Trial.
Strengths of this proposed trial include rigorous design,
inclusion of an inexpensive widely available intervention
and multicenter, international enrolment to maximize
generalizability. Understanding and reducing potential
barriers to enrolment is a critical aim of the PROSPECT
Pilot Trial. Rates of consent are influenced by the ins-
titutional setting, research infrastructure, and experience
of the investigators and research staff [36] as well as
physician-specific concerns [37]. It is therefore essential to
carefully record and monitor enrolment practices and
make improvements where possible. We have successfully
conducted other international trials [38–42] and are inter-
ested to evaluate co-enrolment across participating cen-
ters and countries [43]. When thoughtfully approached,
co-enrolment has not been found to impact on trial
results [43, 44], and thus, ways to maximize safe co-
enrolment opportunities will be explored in this trial.
It is important to understand whether probiotics are
helpful, harmful, or have no effect in vulnerable critically
ill patients. The PROSPECT Pilot Trial is foundational to
this goal. If the future larger PROSPECT Trial shows that
probiotics are effective at preventing VAP, C. difficile, or
any infections in the ICU, use may increase. Conversely, if
the findings suggest harm or no effect, the reverse is likely.
The forthcoming Canadian VAP Prevention Practice
Guidelines which currently “suggest” that probiotics are
considered in practice (J Muscedere, personal communi-
cation, 2015), may, in future updates, either remain the
same, change to “recommend” probiotics, or recommend
against them, depending on our findings.Trial status
Enrolment is underway in the pilot trial.
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PROSPECT Pilot Trial sample size
The sample size for the PROSPECT Pilot Trial was cal-
culated considering a feasibility objective of adherence
to protocol, whereby successful adherence is defined
as ≥90 % of prescribed intervention being administered.
For the sample size of patients, patients are necessarily
the unit of analysis rather than doses prescribed. We will
consider the trial feasible if at least 80 % of the patients
can achieve successful protocol adherence. We based the
calculations on the formula for the sample size for a sin-
gle proportion, based on a confidence interval approach
n≥
p 1−pð Þ z2α=2
 
ME2
where n is the required sample size, p is the prior esti-
mate of the proportion of patients with successful proto-
col adherence, zα/2 = 1.96 is the z-score, a tabulated
value of the standard normal distribution corresponding
to a probability value of 0.05, corresponding to the 95 %
confidence interval (CI), and ME is the margin of error.
We created a table providing different values of the sam-
ple size (n) based on two prior estimates (PE) of p, 0.90
and 0.85, different margins of error (ME), calculated
such that the lower confidence bound (LCB) of the esti-
mated confidence interval estimate will be at least 0.80.
In the PROSPECT Pilot Trial we plan to recruit n = 150
patients, and based on a prior estimate of PE = 0.90, this
will give us an estimate of the proportion of patients
with successful adherence with margin of error between
0.05 and 0.06 and a 95 % CI with a lower bound of 0.84.
Abbreviations
CCTG: Canadian Critical Care Trials Group; CIHR: Canadian Institute of Health
Research; CLARITY: Clinical Advances Through Research and Information
Translation; DSMC: Data Safety and Monitoring Committee; ICU: intensive
care unit; OR: odds ratio; RCT: randomized controlled trial; RR: relative risk;
SAE: serious adverse events; TLR: Toll-like receptor; VAP: ventilator-associated
pneumonia.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JJ, DKH, and DJC conceived of the study. JJ, DKH, JM, MGS, DMB, DJC
contributed to the background of the study. JJ, MM, JM, FL, DKH, MGS, DMB,
LT, and DJC participated in the design of the study. MM, JM, FL, DJC
acquired the data for the study. DJC, JJ, LT drafted the manuscript. MM, JM,
FL, DKH, MGS, DMB revised the manuscript. All read and approved the final
manuscript.
Acknowledgements
The trial was designed by the PROSPECT Steering Committee, the PROTECT
Investigators, and the Canadian Critical Care Trials Group. PROTECT was
supported by the Canadian Critical Care Trials Group.
We are grateful to Dr. E Petrof and Dr. Paul Wischmeyer who consulted in
the planning phases of this trial.Trial funding
This trial was funded by the Canadian Institute of Health Research (CIHR),
Technology Evaluation for the Elderly, Physicians’ Services Incorporated and
the Hamilton Academy of Health Sciences Research Organization. iHealth
provided the blinded study product. None of these groups played a role in
the design, conduct, analysis, interpretation, or write-up of this protocol.Career funding
J Johnstone held a CIHR Fellowship award while preparing the protocol. F
Lauzier is a recipient of a Research Career Award from the Fonds de la
recherche du Québec-Santé. D Cook holds a Chair of the Canadian Institutes
of Health Research.Collaborators
We appreciate the participation of PROSPECT Collaborators as outlined
below:PROSPECT Pilot Trial clinical collaborators
• Dr Maureen Meade, Lori Hand, Hamilton Health Sciences, Hamilton General
Hospital, Hamilton, Ontario
• Dr John Marshall, Orla Smith, Yoon Lee, Julia Lee, Melissa Wang, St
Michael’s Hospital, Toronto, Ontario
• Francois Lauzier, Catherine Ouellet, Sarah-Judith Breton, Marie-Claude
Tremblay, Stephanie Grenier, Hôpital de l’Enfant-Jésus, Québec City, Québec
• Dr Sangeeta Mehta, Brittany Giacomino, Maedean Brown, Sumesh Shah,
Marnie Jakab, Mount Sinai Hospital, Toronto, Ontario
• Dr Peter Dodek, Betty Jean Ashley, Victoria Alcuaz, Kelsey Brewer, St. Paul’s
Hospital, Vancouver, British Columbia
• Dr Lauralyn McIntyre, Irene Watpool, Shelley Acres, Amanda Van Beinum,
Ottawa Hospital, General Campus, Ottawa, Ontario
• Dr Joe Pagliarello, Tracy McArdle, Heather Langlois, Rebecca Porteous, Liane
LeClaire, Shawna Ready, Brigette Gomes, Ottawa Hospital, Civic Campus,
Ottawa, Ontario
• Dr William Henderson, Denise Foster, Susan Logie, Vancouver General
Hospital, Vancouver, British Columbia
• Dr Tim Karachi, Ellen McDonald, Hamilton Health Sciences, Juravinski
Hospital, Hamilton, Ontario
• Dr Eyal Golan, Margaret Herridge, Andrea Matte, Cheryl Geen-Smith, Brooke
Fraser, Sam Kerzner, University Health Network, Western Hospital, Toronto,
Ontario
• Dr Gordon Wood, Daniel Okavim, Fiona Auld, Jennifer Good, Vancouver
Island Health Authority, Victoria, British Columbia
• Dr Deborah Cook, France Clarke, Lois Saunders, Neala Hoad, St Joseph’s
Healthcare, Hamilton, OntarioUnited States investigators
• Dr Rodrigo Carten-Ceba, Laurie Meade, Lavonne Liedl, Brenda Anderson,
Sueanne Weist, Mayo Clinic, Rochester, Minnesota
• Dr Rob Taylor, Katie Krause, Jackie O’Brien, Kim Fowler, Margaret Cytron,
Marianne Tow, St John’s Mercy Hospital, St Louis, Missouri
Author details
1Public Health Ontario, Toronto, Ontario, Canada. 2St. Joseph’s Health Center,
Toronto, Ontario, Canada. 3Department of Medicine, University of Toronto,
Toronto, Canada. 4Department of Medicine, McMaster Health Sciences
Center, Room 2C11, 1200 Main Street W, Hamilton, Ontario, Canada.
5Department of Clinical Epidemiology & Biostatistics, McMaster University,
Hamilton, Canada. 6Department of Surgery, University of Toronto, Toronto,
Canada. 7Interdepartmental Division of Critical Care, University of Toronto,
Toronto, Canada. 8Department of Medicine, Queen’s University, Kingston,
Canada. 9Pathology and Molecular Medicine, McMaster University, Hamilton,
Canada. 10Department of Medicine, Research Center of the CHU de Québec,
Population Health and Optimal Health Practices Research Unit, Québec,
Canada. 11Biostatistics Unit, St Joseph’s Healthcare—Hamilton, Hamilton,
Ontario, Canada.
Received: 23 January 2015 Accepted: 13 May 2015
Johnstone et al. Pilot and Feasibility Studies  (2015) 1:19 Page 7 of 7References
1. Safdar N, Dezfulian C, Collard H, Saint S. Clinical and economic
consequences of ventilator-associated pneumonia: a systematic review.
Crit Care Med. 2005;33:2184–93.
2. Muscedere J, Martin C, Heyland D. The direct burden of illness from
ventilator associated pneumonia. J Crit Care. 2008;23:5–10.
3. Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, Heyland D, et al.
Comprehensive evidence-based clinical practice guidelines for ventilator-
associated pneumonia: prevention. J Crit Care. 2008;23:126–37.
4. Joint FAO/WHO Working Group. Guidelines for the evaluation of probiotics
in food: report of a joint FAO/WHO working group on drafting guidelines
for the evaluation of probitoics in food, London, Ontario, Canada. 2002.
Available at: http://www.fermented-foods.net/wgreport2.pdf. Accessed
December 26, 2014.
5. Marshall J. The gastrointestinal flora and its alterations in critical illness.
Curr Opin Crit Care. 1999;5:119–25.
6. Brenchley J, Douek D. Microbial translocation across the GI tract. Annu Rev
Immunol. 2012;30:149–73.
7. Siempos I, Ntaidou T, Falagas M. Impact of the administration of probiotics
on the incidence of ventilator associated pneumonia: a meta-analysis of
randomized controlled trials. Crit Care Med. 2010;38:954–62.
8. Morrow L, Kollef M, Casale T. Probiotic prophylaxis of ventilator-associated
pneumonia. Am J Respir Crit Care Med. 2010;182:1058–64.
9. Petrof E, Dhaliwal R, Manzanares W, Johnstone J, Cook D, Heyland D.
Probiotics in the critically ill. Crit Care Med. 2012;40(12):3290–302.
10. Hao Q, Lu Z, Dong BR, Huang CQ, Wu T. Probiotics for preventing acute
upper respiratory tract infections. Cochrane Database Syst Rev 2011;
CD006895.
11. Hempel S, Newberry SJ, Maher AR, Wang Z, Miles J, Shanman R, et al.
Probiotics for the prevention and treatment of antibiotic-associated
diarrhea: a systematic review and meta-analysis. JAMA. 2012;307:1959–69.
12. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for
gastrointestinal diseases. PLoS One. 2012;7(4), e34938.
13. Johnson S, Maziade PJ, McFarland LV, Trick W, Donskey C, Currie B, et al. Is
primary prevention of Clostridium difficile infection possible with specific
probiotics? Int J Infect Dis. 2012;16(11):786–92.
14. Ranson J, Rifkind K, Roses D, Fink SD, Eng K, Spencer FC. Prognostic signs
and the role of operative management in acute pancreatitis. Surg Gynecol
Obstet. 1974;139:69–81.
15. Gorbach S. Probiotics and gastrointestinal health. Am J Gastroenterol.
2000;95:S2–4.
16. Wischmeyer PE, Khailova L. Probiotic administration reduces mortality and
improves intestinal epithelial homeostasis in experimental sepsis. Shock.
2012;37:Abstract Supplement.
17. Ferrie S, Daley M. Lactobacillus GG as treatment for diarrhea during enteral
feeding in critical illness: randomized controlled trial. J Parenter Enteral Nutr.
2011;35:43–9.
18. Grossman R, Fein A. Evidence-based assessment of diagnostic tests for
ventilator-associated pneumonia: executive summary. Chest. 2000;117:177S–81.
19. Pugin J, Auckenthaler P, Mill N, Janssens JP, Lew D, Suter PM. Diagnosis of
ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic
and nonbronchoscopic “blind” bronchoalveolar lavage fluid. Am Rev Respir
Dis. 1991;143:1121–9.
20. Heyland D, Muscedere J, Wischmeyer P, Cook DJ, Jones G, Elke G, et al. A
randomized trial of high dose glutamine and anti-oxidants in critically ill
patient with multi-organ failure. N Engl J Med. 2013;368:1489–97.
21. Cook D, Walter S, Cook R, Griffith L, Guyatt G, Leasa D, et al. Incidence of
and risk factors for ventilator-associated pneumonia in critically ill patients.
Ann Intern Med. 1998;129:433–44.
22. Calandra T, Cohen J. For the International Sepsis Forum Definition of
Infection in the ICU Consensus Conference. Crit Care Med. 2005;7:1538–48.
23. Cohen S, Gerding D, Johnson S, Kelly C, Loo V, McDonald L, et al. Clinical
practice guidelines for Clostridium difficile infection in adults: 2010 update
by the Society for Healthcare Epidemiology of America (SHEA) and the
Infectious Diseases Society of America (IDSA). Infect Control Hosp
Epidemiol. 2010;31:431–55.
24. Hickson M, D’Souza AL, Muthu N, Rogers T, Want S, Rajkumar C, et al. Use of
probiotic Lactobacillus preparation to prevent diarrhoea associated with
antibiotics: randomised double blind placebo controlled trial. BMJ.
2007;335(7610):80.25. Cook D, Lauzier F, Rocha MG, Sayles MJ, Finfer S. Serious adverse events in
academic critical care research. CMAJ. 2008;178:1181–4.
26. DAMOCLES Study Group. A proposed charter for clinical trial data
monitoring committees: helping them to do their job well. Lancet.
2005;365:711–22.
27. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, et al. A tutorial on pilot
studies: the what, why and how. BMC Med Res Methodol. 2010;10:1.
http://www.biomedcentral.com/1471-2288/10/1.
28. Arnold DM, Lauzier M, Rabbat C, Zytaruk N, Barlow-Cash B, Clarke F, et al.
Adjudication of bleeding outcomes in an international thromboprophylaxis
trial in critical illness. Thromb Res. 2013;131:204–9.
29. Walter SD, Cook DJ, Guyatt G, King DB, Troyan S. Outcome assessment for
clinical trials: how many adjudicators do we need? Control Clin Trials.
1997;18:27–42.
30. Heels-Ansdell D, Saunders L, Zytaruk N, Southon J, Barlow Cash B, Lutz K,
et al. Methods center personnel costs for adjudication of 5 morbidity
outcomes in a thromboprophylaxis trial. Am Rev Resp Crit Care Med.
2011;183:A1678.
31. Zytaruk N, Meade M, Mehta S, Hall R, Southon J, Heels-Ansdell D, et al.
Adjudication calibration for pulmonary embolism in a thromboprophylaxis
trial. Am J Resp Crit Care Med. 2009;179:A1582.
32. Dodek FLLMIP. Calibration and adjudication of thrombotic events in a
thromboprophylaxis trial Canadian Critical Care Forum abstract book. 2009.
33. Cook DJ, Brower R, Cooper J, Brochard L, Vincent J-L. Multicentre clinical
research in critical care. Crit Care Med. 2002;30:1636–43.
34. Marshall JC, Cook DJ, Canadian Critical Care Trials Group. Investigator-led
clinical research consortia: the Canadian Critical Care Trials Group. Crit Care
Med. 2009;36(7):S165–72.
35. Arnold DA, Burns KE, Adhikari N, Kho ME, Meade MO, Cook DJ. The design
and interpretation of pilot trials in critical care medicine. Crit Care Med.
2009;36(7):S69–74.
36. Smith OM, McDonald E, Zytaruk N, Doster D, Matte A, Clarke F, et al. Rates
and determinants of informed consent: a case study of an international
thromboprophylaxis trial. J Crit Care. 2013;28:28–39.
37. Cook D, Arabi Y, Ferguson N, Heels-Ansdell D, Freitag A, McDonald E, et al.
Physicians declining patient enrollment in a critical care trial: A Case Study
in thromboprophylaxis. Intensive Care Med. 2013;39:2115–25.
38. Lacroix J, Hébert PC, Fergusson D, Tinmouth A, Cook D, Marshall J, et al, for
the ABLE investigators*and the Canadian Critical Care Trials Group. The Age
of Blood Trial in Critically ill Adults. N Engl J Med 2015; DOI:10.1056/
NEJMoa1500704.
39. Heyland D, Muscedere J, Wischmeyer P, Cook D, Jones G, Albert M, et al. A
randomized trial of high dose glutamine and anti-oxidants in critically ill
patient with multi-organ failure. N Engl J Med. 2013;368:1489–97.
40. Ferguson ND, Cook DJ, Guyatt GH, Mehta G, Hand L, Austin P, et al.
High-frequency oscillation in early acute respiratory distress syndrome.
N Engl J Med. 2013;368(9):798–805.
41. Mehta S, Burry LD, Cook DJ, for the SLEAP Investigators and the Canadian
Critical Care Trials Group, et al. Daily sedation interruption in mechanically
ventilated critically ill patients cared for with a sedation protocol: A
randomized controlled trial. JAMA. 2012;308(19):1985–92.
42. Cook DJ, Meade M, Guyatt G, for the PROTECT (Prophylaxis for
ThromboEmbolism in Critical Care Trial) Investigators for the Canadian
Critical Care Trials Group, the Australian and New Zealand Intensive Care
Society Clinical Trials Group, et al. A Randomized Trial of Dalteparin versus
Unfractionated Heparin in Critically Ill Patients. N Engl J Med.
2011;364(14):1305–14.
43. Cook D, McDonald E, Smith O, for the PROTECT Investigators and the
Canadian Critical Care Trials Group, et al. Co-enrollment of critically ill
patients into multiple studies: patterns, predictors and consequences.
Crit Care. 2013;17:R1.
44. Cook DJ, Hand L, Austin P, for the OSCILLATE Investigators and the
Canadian Critical Care Trials Group, et al. Coenrolment in a randomized trial
of high frequency oscillation in ARDS: Prevalence, patterns, predictors and
outcomes. Crit Care Med. 2014;43(2):328–38.
